A Phase IV, Single center, Open-label, Randomized Study to evaluate the Safety and Efficacy of a Tacrolimus twice daily, PROGRAF® versus a Tacrolimus Modified Release, ADVAGRAF®, in stable Liver transplant recipients taking Tacrolimus twice daily.

Trial Profile

A Phase IV, Single center, Open-label, Randomized Study to evaluate the Safety and Efficacy of a Tacrolimus twice daily, PROGRAF® versus a Tacrolimus Modified Release, ADVAGRAF®, in stable Liver transplant recipients taking Tacrolimus twice daily.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Acronyms SMART
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 Apr 2015 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by Korean Clinical Trials Register.
    • 07 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top